Seer, Inc. (SEER) — SEC Filings
Seer, Inc. (SEER) — 32 SEC filings. Latest: DFAN14A (Apr 29, 2026). Includes 10 8-K, 10 SC 13G/A, 6 10-Q.
Overview
Seer, Inc. (SEER) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a DFAN14A filed on Apr 29, 2026: Seer, Inc. filed a DFAN14A on April 29, 2026, related to additional definitive proxy soliciting materials. The filing involves Seer, Inc. (CIK 0001726445) and lists mailing and business addresses for the company in Redwood City, CA. Bradley Louis Radoff (CIK 0001380585) is also listed as a filer.
Sentiment Summary
Across 32 filings, the sentiment breakdown is: 3 bearish, 28 neutral, 1 mixed. The dominant filing sentiment for Seer, Inc. is neutral.
Filing Type Overview
Seer, Inc. (SEER) has filed 1 DFAN14A, 10 8-K, 6 10-Q, 2 DEF 14A, 1 10-K/A, 2 10-K, 10 SC 13G/A with the SEC between Jan 2024 to Apr 2026.
Filings by Year
Recent SEC Filings (32)
Risk Profile
Risk Assessment: Of SEER's 23 recent filings, 2 were flagged as high-risk, 11 as medium-risk, and 10 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $4.12M |
| Net Income | -$18.2M |
| EPS | N/A |
| Debt-to-Equity | 0.14 |
| Cash Position | $251.2M |
| Operating Margin | N/A |
| Total Assets | $308.61M |
| Total Debt | $36.79M |
Key Executives
- Bradley Louis Radoff
- Dr. Robert T. Baser
- Dr. Jonathan S. Rothberg
- Dr. Omid Farokhzad
- Dr. Piero Carbone
- Omid Farokhzad
- Chief Executive Officer
- Dr. Priya Bhanu
- Dr. David R. Walt
- Ms. Sarah E. Emrey
- Dr. Daniel R. Spiegel
- Omid Farokhzad, M.D.
- David Horn
- Abigail P. Johnson
Industry Context
Seer, Inc. operates in the rapidly evolving biotechnology and diagnostics sector, characterized by significant R&D investment, long product development cycles, and intense competition. Key trends include the increasing demand for advanced diagnostic tools, personalized medicine, and data-driven healthcare solutions. Companies in this space often face challenges related to regulatory approvals, market adoption, and the need for substantial capital to fund innovation and commercialization.
Top Tags
10-Q (4) · financials (4) · institutional-ownership (4) · Biotechnology (3) · amendment (3) · Proteomics (2) · Net Loss (2) · executive-compensation (2) · corporate-governance (2) · Proxy Statement (2)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Net Loss (Q3 2025) | $18.2M | Improved from $21.3M in Q3 2024, a 14.5% reduction. |
| Total Revenue (Q3 2025) | $4.12M | Increased from $4.03M in Q3 2024, a 2.2% increase. |
| Service Revenue (Q3 2025) | $913K | Increased from $661K in Q3 2024, a 38.1% increase. |
| Product Revenue (Q3 2025) | $2.76M | Decreased from $2.92M in Q3 2024, a 5.5% decrease. |
| R&D Expense (Q3 2025) | $10.8M | Decreased from $13.0M in Q3 2024, a 16.7% reduction. |
| SG&A Expense (Q3 2025) | $10.7M | Decreased from $13.3M in Q3 2024, a 19.8% reduction. |
| Cash & Investments (Sept 30, 2025) | $251.2M | Provides liquidity for at least 12 months despite ongoing losses. |
| Accumulated Deficit (Sept 30, 2025) | $450.0M | Indicates significant historical losses since inception. |
| International Revenue (Q3 2025) | 48% | Increased from 29% in Q3 2024, showing growing global presence. |
| Total Shares Outstanding (Sept 30, 2025) | 55,786,344 | Reflects share repurchases reducing outstanding shares. |
| Net Loss for Q2 2025 | $25.3M | increased from $20.1M in Q2 2024 |
| Revenue for Q2 2025 | $5.5M | up 14.6% from $4.8M in Q2 2024 |
| Research and Development Expense for Q2 2025 | $15.1M | increased from $13.5M in Q2 2024 |
| Selling, General, and Administrative Expense for Q2 2025 | $13.5M | increased from $10.9M in Q2 2024 |
| Cash and Cash Equivalents as of June 30, 2025 | $150.2M | decreased from $175.5M at December 31, 2024 |
Forward-Looking Statements
- {"claim":"Seer, Inc.'s stock price may experience downward pressure in the short term.","entity":"Seer, Inc.","targetDate":"3 months","confidence":"medium"}
- {"claim":"Other institutional investors might re-evaluate their positions in Seer, Inc.","entity":"Institutional Investors","targetDate":"6 months","confidence":"medium"}
- {"claim":"FMR LLC will maintain a significant ownership stake in Seer, Inc. for the foreseeable future.","entity":"FMR LLC","targetDate":"2025-02-09","confidence":"high"}
- {"claim":"The continued institutional ownership by FMR LLC will provide a floor for Seer, Inc.'s stock price.","entity":"Seer, Inc.","targetDate":"2024-08-09","confidence":"medium"}
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Seer, Inc. (SEER)?
Seer, Inc. has 32 recent SEC filings from Jan 2024 to Apr 2026, including 10 8-K, 10 SC 13G/A, 6 10-Q. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of SEER filings?
Across 32 filings, the sentiment breakdown is: 3 bearish, 28 neutral, 1 mixed. The dominant sentiment is neutral.
Where can I find Seer, Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Seer, Inc. (SEER) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Seer, Inc.?
Key financial highlights from Seer, Inc.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for SEER?
The investment thesis for SEER includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Seer, Inc.?
Key executives identified across Seer, Inc.'s filings include Bradley Louis Radoff, Dr. Robert T. Baser, Dr. Jonathan S. Rothberg, Dr. Omid Farokhzad, Dr. Piero Carbone and 9 others.
What are the main risk factors for Seer, Inc. stock?
Of SEER's 23 assessed filings, 2 were flagged high-risk, 11 medium-risk, and 10 low-risk.
What are recent predictions and forward guidance from Seer, Inc.?
Recent forward-looking statements from Seer, Inc. include guidance on {"claim":"Seer, Inc.'s stock price may experience downward pressure in the short term.","entity":"Seer, Inc.","targetDat and 3 other predictions.